{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-027017","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.759174+00:00","generated_at":"2026-06-20T23:17:53.054046+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Heart Test Labs receives Nasdaq deficiency notice for failing minimum equity requirement","bullets":["Nasdaq letter dated Dec 21, 2022: stockholders' equity ($1.08M) below $2.5M minimum required by Listing Rule 5550(b)(1).","Company has 45 days (until Feb 3, 2023) to submit a compliance plan; Nasdaq may grant up to 180 days to regain compliance.","If plan not accepted or compliance not regained, trading suspension or delisting risk, negatively impacting liquidity and financing.","Company intends to take measures to regain compliance; is evaluating options."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-027017","json":"https://secwatch.observer/filing/0000950170-22-027017.json","markdown":"https://secwatch.observer/filing/0000950170-22-027017.md","text":"https://secwatch.observer/filing/0000950170-22-027017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017022027017/0000950170-22-027017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017022027017/hscs-20221223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:17:53.054046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92cb6de726f9d0d282af3ac4e93a8748b4b7f986","claim":"HeartSciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"December 21, 2022, Heart Test Laboratories, Inc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report for the period ended October 31, 2022, the Company reported stockholders’ equity of $1,082,676, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Com","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017022027017/0000950170-22-027017-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}